Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism
Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism
批准号:
8771201
负责人:
Robert A Rissman
金额:
$19.38万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2016-04-30
关键词:
AblationAge-MonthsAlzheimer&aposs DiseaseAmyloidAnimalsAttenuatedBiochemicalBiochemical MarkersBloodBrainCRF receptor type 1ChronicCognitionCognitiveCognitive deficitsCombined Modality TherapyDataDevelopmentDilatation - actionDoseEarly treatmentEventGenerationsGeneticGleanGoalsHippocampus (Brain)Impaired cognitionMeasurementMediator of activation proteinMemoryMemory impairmentMonitorMusNerve DegenerationNeurofibrillary TanglesPathologyPathway interactionsPerformancePharmaceutical PreparationsProductionProtocols documentationShort-Term MemorySignal TransductionStagingStressTauopathiesTestingTherapeuticTransgenic MiceTransgenic OrganismsTranslatingVentricularWorkage groupamyloid pathologydrug efficacyextracellulargamma secretasehyperphosphorylated tauimprovedmouse modelneuropathologynovelpreventpublic health relevanceresearch studysmall moleculetau Proteinstau aggregationtau phosphorylationtransgenic model of alzheimer disease
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is defined neuropathologically by extracellular plaques composed of ¿-amyloid (A¿) and intracellular tangles consisting of hyperphosphorylated forms of the microtubule-associated protein tau. A¿ accumulation and hyperphosphorylation of tau are recognized as key events leading to full blown AD neuropathology. Here we propose to use a unique set of small molecule drugs (gamma-secretase modulators and CRFR1 antagonists) to further explore novel AD therapeutics. This application will focus on the efficacy of drugs aimed at both A¿- and tau-related pathologies in AD transgenic mice. Our overarching hypothesis is combination therapy aimed to disrupt production of both A¿42 and hyperphosphorylated tau will be an efficacious treatment approach for prodromal or early AD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HABS-HD - Core D - Omics Core
-
批准号:10493848
-
项目类别:
-
资助金额:$918.05万
-
财政年份:2022
-
负责人:Robert A Rissman
-
依托单位:
Novel Systemic Delivery of Peptide-Mediated Anti-Sense Oligonucleotides for Dementia with Lewy Bodies
-
批准号:10186335
-
项目类别:
-
资助金额:$175.11万
-
财政年份:2021
-
负责人:Robert A Rissman
-
依托单位:
Novel Antagonists of the N-terminal Domain of the CRF Receptor Type 1 for Alzheimer's Disease
-
批准号:10433769
-
项目类别:
-
资助金额:$35.45万
-
财政年份:2020
-
负责人:Robert A Rissman
-
依托单位:
Neuropathology Core
-
批准号:10407982
-
项目类别:
-
资助金额:$29.22万
-
财政年份:2019
-
负责人:Robert A Rissman
-
依托单位:
Biomarker Core
-
批准号:10615171
-
项目类别:
-
资助金额:$23.22万
-
财政年份:2019
-
负责人:Robert A Rissman
-
依托单位:
Neuropathology Core
-
批准号:10615167
-
项目类别:
-
资助金额:$31.24万
-
财政年份:2019
-
负责人:Robert A Rissman
-
依托单位:
Biomarker Core
-
批准号:10407984
-
项目类别:
-
资助金额:$21.82万
-
财政年份:2019
-
负责人:Robert A Rissman
-
依托单位:
Proteomic characterization of exosomes from AD patients
-
批准号:9563205
-
项目类别:
-
资助金额:$84.4万
-
财政年份:2017
-
负责人:Robert A Rissman
-
依托单位:
Pathogenicity of neuronally-derived tau in exosomes
-
批准号:9336219
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2016
-
负责人:Robert A Rissman
-
依托单位:
Validation Studies of CRF Receptor 1 as a Target for AD
-
批准号:9325287
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Robert A Rissman
-
依托单位:
Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism
-
批准号:8917840
-
项目类别:
-
资助金额:$22.55万
-
财政年份:2014
-
负责人:Robert A Rissman
-
依托单位:
Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis
-
批准号:7898638
-
项目类别:
-
资助金额:$37.84万
-
财政年份:2008
-
负责人:Robert A Rissman
-
依托单位:
Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis
-
批准号:7508580
-
项目类别:
-
资助金额:$39.11万
-
财政年份:2008
-
负责人:Robert A Rissman
-
依托单位:
Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis
-
批准号:7673344
-
项目类别:
-
资助金额:$40.09万
-
财政年份:2008
-
负责人:Robert A Rissman
-
依托单位:
Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis
-
批准号:8105068
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2008
-
负责人:Robert A Rissman
-
依托单位:
Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis
-
批准号:8309237
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2008
-
负责人:Robert A Rissman
-
依托单位:
Role of Intracellular ABeta in Tau Pathology
-
批准号:6738775
-
项目类别:
-
资助金额:$4.16万
-
财政年份:2004
-
负责人:Robert A Rissman
-
依托单位:
a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease
-
批准号:10360204
-
项目类别:
-
资助金额:$39.5万
-
财政年份:2001
-
负责人:Robert A Rissman
-
依托单位:
a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease
-
批准号:10232069
-
项目类别:
-
资助金额:$50.63万
-
财政年份:2001
-
负责人:Robert A Rissman
-
依托单位:
BIOMARKER CORE
-
批准号:8601648
-
项目类别:
-
资助金额:$21.7万
-
财政年份:--
-
负责人:Robert A Rissman
-
依托单位: